PubRank

New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 26939044)

Published in J Mol Graph Model on February 26, 2016

Authors

Francesco Gentile1, Jack A Tuszynski2, Khaled H Barakat3

Author Affiliations

1: Department of Physics, University of Alberta, Edmonton, AB, Canada.
2: Department of Physics, University of Alberta, Edmonton, AB, Canada; Department of Oncology, University of Alberta, Edmonton, AB, Canada.
3: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. Electronic address: kbarakat@ualberta.ca.

Articles citing this ↘

Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75

Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs. Oncotarget (2016) 0.75

Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1. Oncotarget (2017) 0.75

Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int J Clin Oncol (2017) 0.75